Seattle Genetics Has Successfully Finished SGN-30 Study
DOW JONES NEWSWIRES
BOTHELL, Wash. -- Seattle Genetics Inc. (SGEN) plans to launch a second trial of its monoclonal antibody SGN-30 later this year following a successfully completed first phase I trial.
Under that study, which treated 13 patients with hematologic malignancies such as Hodgkin's disease, results showed that SGN-30 was well-tolerated up to a single dose of 15 milligrams per kilogram with no drug-related toxicities observed.
Preclinical data announced in July showed that SGN-30 induces tumor cell death, or apoptosis, in culture and is efficacious in models of Hodgkin's disease.
In a press release Wednesday, the developer of antibody-based therapeutics said it will design the next trial as a phase I/II multi-dose study.
Additionally, Seattle Genetics said it is currently investigating the use of SGN-30 for the treatment of autoimmune disease in preclinical models.
Shares of Seattle Genetics recently traded at $2.75, down 14 cents, or 4.8%, on Nasdaq volume of 20,500 shares. Average daily volume is 59,664 shares. The company's shares recently hit a 52-week low of $2.62 on Tuesday, compared to a 52-week high of $7.50 on Jan. 15. |
